Glaucoma treatment
AssigneesThe Research Foundation for The State University of New York, Icahn School of Medicine at Mount Sinai
InventorsIoannis Danias, Oscar A. Candia, Rosana Gerometta
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.
Claims18
A method of treatment for chronic elevated intraocular pressure (IOP) in a subject, the method comprising:
- administering to said subject a therapeutically effective amount of a tissue plasminogen activator (tPA) or a recombinant tPA variant for a period of at least two weeks, wherein the therapeutically effective amount of tPA or recombinant tPA variant is administered at a dosage of 10-120 μl per dose.
A method of treatment for a chronic elevated intraocular pressure (IOP) in a subject, comprising:
- administering to said subject a therapeutically effective amount of a tissue plasminogen activator (tPA) or recombinant tPA variant for a period of at least two weeks, wherein the therapeutically effective amount is in the range of 10 μg to 120 μg.
Dependencies are inferred from the claim text.